Updated September 2026: Self-pay prices for Wegovy and Zepbound have both come down since this post first ran, a new oral option (Foundayo) now has its own cash price through Lilly, and a federal deal put a government storefront, TrumpRx.gov, and a temporary Medicare benefit into the middle of the picture.

Patients and colleagues ask me often about the cost of GLP-1 medications when insurance does not cover them. Wegovy, Zepbound, and now Foundayo are all FDA approved for chronic weight management, and I prescribe all three by video visit. The barrier that brings people to this post hasn’t changed: their plan excludes the drug category outright, no prior authorization appeal is going to fix that, and the retail cash price at a corner pharmacy is still well over a thousand dollars a month (10).

What Actually Changed

A year ago the only option was NovoCare’s flat $499 rate for Wegovy and Lilly’s roughly $500 rate for Zepbound. In 2025 I had a patient who had already tried to fill Wegovy at a local pharmacy. The pharmacist quoted her a cash price over $1,300. She couldn’t afford that. Under NovoCare’s program as it existed then, she could have her prescription sent to NovoCare Pharmacy for $499 a month instead. That flat rate is gone now. Both companies have rebuilt their self-pay pricing since then, and a November 2025 deal between the White House and both manufacturers pushed cash prices down further and set the stage for a new Medicare benefit (8). What you get in September 2026 is a tiered price ladder instead of one flat number, and most doses cost less than they did a year ago.

Wegovy: Injection and Pill, Two Different Price Ladders

NovoCare Pharmacy remains Novo Nordisk’s direct-to-consumer channel for patients paying cash. If your plan covers Wegovy, a separate commercial savings card is the better deal and can bring a copay down near zero; that’s a different program from what’s below. As of this September, the injectable pen runs $349 a month for the standard dose range and $399 a month for the newer HD 7.2 mg strength, with a $199 introductory rate for a patient’s first two monthly fills that Novo has said will hold through the end of 2026 (1). The oral tablet, approved in December 2025 and launched in January 2026 as the first pill-form GLP-1 for obesity, is priced in three tiers: $149 for the starter dose, $199 for the next step up, and $299 once a patient reaches a maintenance strength (1). Both require the prescription to be filled through NovoCare specifically. A local pharmacy handed the same script will still quote the full list price, somewhere north of $1,300 (10).

Zepbound: LillyDirect’s Vial and Pen Pricing

Lilly runs a comparable program under LillyDirect, and the vial and the single-patient-use KwikPen are priced identically by dose: $299 for the 2.5 mg starting dose, $399 at 5 mg, and $449 across the 7.5 to 15 mg range (4). That top tier has a catch: the $449 rate only holds if the patient refills within 45 days of the last delivery. Miss the window and the price reverts to $499 for 7.5 mg or $699 for the higher strengths (4, 5). It is an easy detail to overlook when a patient is titrating slowly or pauses therapy for a few weeks.

Foundayo: The Oral Option From Lilly

Foundayo (orforglipron) is Lilly’s oral small-molecule GLP-1, approved this spring and priced through the same LillyDirect infrastructure: $149 at the 0.8 mg starting dose, $199 at 2.5 mg, and $299 across the maintenance range from 5.5 mg up through 17.2 mg (6). Lilly’s own pricing page wasn’t accessible when this update was written, so these numbers come from a pharmaceutical trade publication that reported them the week Foundayo launched. Check the live page before quoting a patient a number.

Medicare, Medicaid, and the Federal Programs

Government coverage intersects this topic in two separate ways, and they are easy to conflate.

The first is eligibility for the manufacturer self-pay programs themselves, and the two companies handle it differently. NovoCare’s own program terms allow a patient enrolled in Medicare, Medicaid, TRICARE, or another government plan to use the Wegovy or Wegovy-pill self-pay price, as long as they pay the full cash price, do not bill their government coverage for it, and do not count it toward a deductible or Part D out-of-pocket total (2). LillyDirect’s Zepbound Self Pay Journey Program works the other way: its terms require that a patient not be enrolled in any state or federal government healthcare program at all, including Medicare, Medicaid, TRICARE, and VA, to use the self-pay price (4). I could not find published eligibility terms for Foundayo’s self-pay program, so I’m not assuming it follows Zepbound’s rule.

The second is an actual Medicare drug benefit, the Medicare GLP-1 Bridge, a temporary demonstration built from the same November 2025 deal. It started July 1, 2026 and runs through December 31, 2027. It covers Foundayo, all formulations of Wegovy, and the Zepbound KwikPen, though not the Zepbound vial, for a $50 monthly copay under Medicare Part D. A beneficiary has to meet BMI and health-condition criteria, such as type 2 diabetes or cardiovascular disease, and the prescriber has to get it prior-authorized (11). This runs through a regular pharmacy claim, not a manufacturer cash-pay program, and has been active a little over two months.

TrumpRx.gov, the federal storefront that launched in February, lists the Wegovy pill at $149 a month and the Wegovy pen at $199, alongside Ozempic at $199 (7). The pen price matches NovoCare’s own first-two-fills introductory rate rather than the ongoing $349 rate, and the site appears to route orders through the same manufacturer pharmacies rather than operating as an independent seller.

Current Self-Pay Prices at a Glance

Product	Dose / Tier	Self-Pay Price	Notes
Wegovy pen (NovoCare)	0.25 to 2.4 mg	$349/mo	$199/mo for first two fills through Dec 31, 2026
Wegovy pen HD (NovoCare)	7.2 mg	$399/mo
Wegovy pill (NovoCare)	Starter dose	$149/mo
Wegovy pill (NovoCare)	Step-up dose	$199/mo
Wegovy pill (NovoCare)	Maintenance dose	$299/mo
Zepbound vial or KwikPen (LillyDirect)	2.5 mg	$299/mo
Zepbound vial or KwikPen (LillyDirect)	5 mg	$399/mo
Zepbound vial or KwikPen (LillyDirect)	7.5 to 15 mg	$449/mo	Requires refill within 45 days, otherwise $499 to $699/mo
Foundayo (LillyDirect)	0.8 mg starter	$149/mo	Not independently confirmed on Lilly’s site; see notes
Foundayo (LillyDirect)	2.5 mg	$199/mo	Same caveat
Foundayo (LillyDirect)	5.5 to 17.2 mg maintenance	$299/mo	Same caveat
Medicare GLP-1 Bridge (Part D)	Foundayo, Wegovy, Zepbound KwikPen only	$50/mo copay	Started July 1, 2026; requires prior authorization and BMI/condition criteria
TrumpRx.gov	Wegovy pill	$149/mo	Mirrors NovoCare price
TrumpRx.gov	Wegovy pen	$199/mo	Introductory rate only
Retail list price, no program	Wegovy	~$1,349 to $1,650/mo	GoodRx average
Retail list price, no program	Zepbound	~$1,060 to $1,271/mo	GoodRx average

The Compounding Chapter Is Closed

Patients still ask about compounded semaglutide and tirzepatide. The versions that filled the gap during the 2023 to 2024 shortage are no longer a legitimate mass option. FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, and the grace periods for 503A and 503B compounders to wind down ended by mid-2025 (9). This April, FDA moved to formally strike both drugs from the bulk compounding list, closing the loophole some pharmacies had used to keep producing modified formulations. A narrow carve-out remains for pharmacies filling four or fewer prescriptions of a drug per month, but that isn’t the shortage-era product (9). If a telehealth company is still advertising a cheap compounded semaglutide or tirzepatide product, ask hard questions before filling it.

For Patients

Eligibility for the self-pay price is not the same across both companies, and it is worth reading the actual terms rather than assuming. NovoCare allows patients with Medicare, Medicaid, TRICARE, or VA coverage to use the Wegovy self-pay price if they pay cash and don’t bill their government plan for it. LillyDirect’s Zepbound self-pay program excludes anyone enrolled in a government health plan regardless of how they intend to pay. If you have Medicare Part D and meet the clinical criteria, ask your prescriber about the GLP-1 Bridge instead; it covers Foundayo, Wegovy, and the Zepbound KwikPen for a $50 copay. Whichever route applies to you, the prescription has to be routed to the correct pharmacy to get that price. Handing the same script to your neighborhood pharmacist and expecting the discounted rate will not work.

For Clinicians

Both LillyDirect and NovoCare are really good in my experience. The paperwork is less than most insurance companies require, and both platforms are quick to get medications out to patients. I like them equally. Two details are worth flagging with patients: the refill-window trap on Zepbound’s top-tier pricing, and the fact that TrumpRx’s price for the Wegovy pen is a promotional rate rather than the standing one. Setting expectations for month three matters as much as month one. Eligibility terms differ by manufacturer too, so confirm which program a given patient’s coverage actually qualifies for before writing the prescription.

The Bottom Line

Wegovy and Zepbound both cost less than they did a year ago, and two oral options now sit at the bottom of the price range. A $199 to $349 monthly price for Wegovy, or $299 to $449 for Zepbound, is a different number than $1,300 a month, even though it is still a real expense for most households. Whether a government-insured patient can use self-pay pricing depends on the manufacturer: NovoCare permits it, LillyDirect does not, and qualifying Medicare Part D enrollees have a separate $50 option through the GLP-1 Bridge. None of it works if the prescription goes to the wrong pharmacy. Confirm the current terms before committing to a plan; this class of drug has changed its pricing and its rules more than once a year for three years running.

Related Reading

Compounded Semaglutide and Tirzepatide: What to Know Now Foundayo vs. the Wegovy Pill: Comparing the Two New Weight Loss Pills Wegovy 7.2 mg: Who Should Consider the Higher Dose? Weight Loss Medications for Kids and Adults Explained Doctor Supervised Weight Loss: What Works Long Term

Scott Rennie, D.O.
Board Certified in Obesity Medicine and Family Medicine

This blog is for educational purposes only and does not constitute individual medical advice. Always consult your own physician before making changes to your health, medications, or treatment plan.

Sources

1. Novo Nordisk, NovoCare Pharmacy self-pay pricing for Wegovy, novocare.com/patient/medicines/wegovy.html, accessed September 11, 2026.
2. Novo Nordisk, NovoCare Pharmacy Terms and Conditions of Use (self-pay eligibility for government-insured patients), novocare.com/eligibility/pharmacy.html, accessed September 11, 2026.
3. Novo Nordisk, “Novo Nordisk introduces NovoCare Pharmacy, lowering cost of all doses of FDA-approved Wegovy (semaglutide) to $499 per month,” prnewswire.com, August 5, 2025 (program launch, price since superseded, cited for history only).
4. Eli Lilly, Zepbound coverage, savings, and self-pay eligibility, zepbound.lilly.com/hcp/coverage-savings, accessed September 11, 2026.
5. Eli Lilly, “Lilly lowers the price of Zepbound (tirzepatide) single-dose vials,” investor.lilly.com, accessed via search September 11, 2026 (direct page fetch timed out; figures cross-checked against source 4).
6. PharmExec, “FDA Approves Foundayo Under National Priority Voucher Program,” pharmexec.com/view/fda-approves-foundayo-under-national-priority-voucher-program, April 1, 2026.
7. TrumpRx.gov, GLP-1 medication pricing listing, trumprx.gov, accessed September 11, 2026.
8. NBC News, “Trump administration weight loss drugs deal,” nbcnews.com/health/health-news/trump-weight-loss-drugs-wegovy-zepbound-lower-price-deal-rcna241929, November 4, 2025.
9. U.S. Food and Drug Administration, “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize,” fda.gov, updated April 1, 2026.
10. GoodRx, Wegovy and Zepbound price pages, goodrx.com/wegovy and goodrx.com/zepbound, accessed September 11, 2026.
11. KFF, “What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge,” kff.org, updated May 11, 2026.